Armata Pharmaceuticals, Inc. Annual Report: How They Did This Year

I’ve put together this guide to help you understand Armata Pharmaceuticals’ performance over the past year. My goal is to translate complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Armata is a biotech company developing "phage therapeutics." Unlike traditional antibiotics that kill both good and bad bacteria, Armata’s treatments target specific, antibiotic-resistant germs like Staphylococcus aureus.

The company is currently in the research phase and generates no sales revenue. Their success depends on moving their treatments through clinical trials, protecting their 100+ patents, and managing their cash carefully while working toward FDA approval.

2. Financial health: The "Burn Phase"

Armata is in a "burn phase," meaning they spend heavily on research without bringing in money from product sales.

• Market Value: As of mid-2025, the company is valued at about $21.1 million, reflecting the high-risk nature of early-stage biotech.
• Funding: The company relies on Innoviva Strategic Opportunities LLC for support. In August 2025, Armata secured a $15 million loan. In December, they launched a program to sell up to $100 million in new stock to fund operations.
• The Reality: The company lost about $48.2 million this year, mostly due to $36.5 million in research costs. With only $12.4 million in cash left, their survival depends on Innoviva’s continued support and their ability to sell that new stock.

3. Major wins: The "diSArm" Breakthrough

The company’s most important project is AP-SA02, a treatment for Staphylococcus aureus blood infections.

• The Results: In a recent study, patients treated with AP-SA02 alongside standard antibiotics had an 88% response rate. The group receiving only standard antibiotics saw a 58% response rate. The treatment group had zero relapses and no serious drug-related side effects.
• FDA Validation: The FDA granted AP-SA02 "Fast Track" status. This helps the company communicate with the FDA more easily, speeds up the review process, and adds five years of market exclusivity if the drug is approved.

4. Key risks for investors

• Dilution: The $100 million stock-selling program means the company will issue more shares. This reduces your ownership percentage unless you buy more shares yourself.
• "Going Concern" Risk: Auditors warned that the company may not have enough cash to last the next 12 months. If they cannot raise more money or find a partner, the business may not survive.
• Clinical Uncertainty: While early results look good, Phase 3 trials are larger and harder to pass. If the upcoming 450-patient trial fails, the company’s main asset—and its value—could disappear.

5. Future outlook

Armata is moving toward a major Phase 3 trial for AP-SA02, starting in late 2026. This study will definitively test if the treatment is safe and effective. Success here is required to apply for FDA approval. If the data holds up, Armata hopes to make AP-SA02 the new standard for treating dangerous hospital infections.

Note: This guide is based on the 2025 Annual Report. While clinical progress is promising, the company remains a high-risk bet on future trial success and their ability to keep raising cash. Before investing, consider whether you are comfortable with the possibility of share dilution and the company's current reliance on external funding to stay afloat.